Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Attacks Antibiotic Overuse, Putting Pressure on Makers’ Stock Prices

publication date: Oct 7, 2011
China's doctors and patients love antibiotics. Although the country’s consumption of pharma products remains low, its antibiotic use is disproportionately high. Unfortunately, there is a price for heavy use of antibiotics: the PRC has high levels of drug-resistant infections, especially in tuberculosis and urinary tract infections. In an attempt to stop this trend, China's government is trying to curb overuse of antibiotics, which is having a negative effect on the stock prices of  pharmas that make these products. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital